Murthy SB, Biffi A, Falcone GJ, et al. - Researchers conducted this multicenter cohort to explore the link between antiplatelet therapy after intracerebral hemorrhage (ICH) and functional outcomes. Data were meta-analyzed from the Massachusetts General Hospital ICH registry (n = 1,854), the Virtual International Stroke Trials Archive database (n = 762), and the Yale stroke registry (n = 185). The study population included 2,801 ICH patients. Two hundred eighty-eight ICH patients were started on antiplatelet medications after ICH. Data reported that median time ranged from 7 to 39 days for antiplatelet therapy. Following ICH, the anti-platelet treatment seemed safe and was not linked to all-cause mortality or functional outcome regardless of the location of the hematoma. To evaluate the benefits and harms of antiplatelet therapy after ICH, randomized clinical trials are required.